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Abstract
Background: Poor recruitment of patients is the predominant reason for early termination of randomized clinical
trials (RCTs). Systematic empirical investigations and validation studies of existing recruitment models, however, are
lacking. We aim to provide evidence-based guidance on how to predict and monitor recruitment of patients into
RCTs. Our specific objectives are the following: (1) to establish a large sample of RCTs (target n = 300) with
individual patient recruitment data from a large variety of RCTs, (2) to investigate participant recruitment patterns
and study site recruitment patterns and their association with the overall recruitment process, (3) to investigate the
validity of a freely available recruitment model, and (4) to develop a user-friendly tool to assist trial investigators in
the planning and monitoring of the recruitment process.
Methods: Eligible RCTs need to have completed the recruitment process, used a parallel group design, and
investigated any healthcare intervention where participants had the free choice to participate. To establish the
planned sample of RCTs, we will use our contacts to national and international RCT networks, clinical trial
units, and individual trial investigators. From included RCTs, we will collect patient-level information (date of
randomization), site-level information (date of trial site activation), and trial-level information (target sample
size). We will examine recruitment patterns using recruitment trajectories and stratifications by RCT
characteristics. We will investigate associations of early recruitment patterns with overall recruitment by
correlation and multivariable regression. To examine the validity of a freely available Bayesian prediction
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model, we will compare model predictions to collected empirical data of included RCTs. Finally, we will user-
test any promising tool using qualitative methods for further tool improvement.
Discussion: This research will contribute to a better understanding of participant recruitment to RCTs, which
could enhance efficiency and reduce the waste of resources in clinical research with a comprehensive,
concerted, international effort.
Keywords: Recruitment, Accrual, Prediction, Randomized clinical trials
Background
Randomized clinical trials (RCTs) are considered standard
to evaluate benefits and harms of healthcare interventions.
RCTs are major undertakings that require enormous
resources and coordination of multiple stakeholders. One
out of four RCTs is prematurely discontinued because of
poor recruitment of participants, other reasons suggesting
futility, unexpected harm, early superiority, or administra-
tive problems [1–4]. The leading reason for discontinuation
is poor recruitment [5]. In particular, investigator-initiated
RCTs with smaller sample size carry the highest risk for
premature discontinuation due to poor patient recruitment.
Such discontinued RCTs are also less likely to be published
in medical journals [5].
Early discontinuation for poor recruitment is problem-
atic: First, the pertinent research question typically re-
mains unanswered. Second, precious resources for clinical
research are wasted if costly RCTs need to be discontin-
ued because of overoptimistic recruitment assumptions, in
particular, if whatever results and lessons learned remain
unpublished [6]. Third, public and patients’ trust and will-
ingness to participate in clinical studies are compromised
if RCTs are not professionally planned and conducted to
minimize the risk for insufficient recruitment.
A central question for investigators during planning
and conducting RCTs is: Given the expected number of
participating centers and number of patients per center,
how long will it take to recruit the target number of
patients? Once the trial has started recruiting, the
central question changes into: Given the recruitment
data we have so far, how long will it take to recruit the
target number of patients now, and do we have to adjust
our initial estimates and plans?
Therefore, evidence-based guidance and tools to
predict and monitor recruitment of patients to RCTs are
needed [7]. Methodological research on recruitment to
clinical trials has increasingly become of interest to
clinical researchers; exemplary initiatives are the working
group by the Medical Research Council (UK) [8], the
Clinical Trials Transformation Initiative (CTTI) [9], and
the Trial Forge-collaboration [10].
A recent systematic review on recruitment models
identified 13 articles reporting on different recruitment
models and provides a comprehensive exploration on
recruitment topics from a statistical perspective [11]. Of
note, while in some of the studies a validation of
proposed models is reported, systematic empirical inves-
tigations and validation studies of proposed recruitment
models with large datasets are still lacking.
One of the identified models was a Bayesian model de-
veloped by Jiang et al. [12] with an open source package
for the statistical program R [13]. This model requires
only input information that is readily available to trialists
and trial coordinators, such as planned sample size,
anticipated time needed for total trial recruitment,
number of patients recruited to date, and interim time
point (e.g., 6 months after trial initiation). Given the
recruitment process until the interim time point, the
program allows either calculating the time needed to
recruit the remaining number of patients or predicting
anticipated recruitment over a given period of time. The
program provides a predicted time accompanied by a
prediction interval and illustrative plots.
We initiated the international collaborative project on
RECRUITment In Trials (RECRUIT-IT) to investigate
performance of the Bayesian recruitment model developed
by Jiang et al. [12] to provide evidence-based recommenda-
tions for the planning and monitoring of patient recruit-
ment in RCTs.
We aim to accomplish this goal through four specific
objectives:
1. To establish a large database with empirical
individual patient recruitment data from a
variety of RCTs.
2. To investigate overall participant recruitment
patterns of RCTs and recruitment patterns at
individual study sites and their association with the
overall recruitment process.
3. To investigate the validity of the freely available
Bayesian recruitment model [12] to predict
participant recruitment into RCTs.
4. To refine the recruitment model from objective
3 or to develop a new model based on the
findings from objectives 1–3 for an interactive
and user-friendly tool to assist trial investigators
in the planning and monitoring of the
recruitment process.
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Methods/design
Study design and eligibility criteria
This project will be based on empirical recruitment data
from RCTs. We will include parallel group RCTs that
have completed or terminated the recruitment process
for all participating trial sites, evaluating any healthcare
intervention where participants had the free choice to
participate. Ideally, individual recruitment data (the date
of randomization for each patient) are available; however,
RCTs with recruitment data aggregated on a monthly
basis will also be included. There will be no limitation
with respect to sample size, medical field, intervention,
jurisdiction, or funding source. However, we will exclude
RCTs if they meet one of the following criteria, of which
we assume that such studies are less attractive for partici-
pants than other trials, with inherent implications for
recruitment patterns:
1. The trial investigated pharmacokinetics only.
2. The trial was actually a sub-study of a trial (e.g.,
whereby the main outcomes are biomarker studies).
3. The trial was a pilot trial (e.g., whereby the main
outcomes are related to feasibility).
Selection of RCTs and sample size
We aim to include RCTs from the following research
groups that we approached through our personal networks:
(i) AIDS Clinical Trials Group (ACTG) [14, 15], (ii) Paris
Hospital Network (Assistance publique – Hôpitaux de
Paris), (iii) Swiss Group for Clinical Cancer Research
(SAKK), (iv) Johns Hopkins Medical Institutions, (v) clinical
researchers from the university hospitals Basel and Bern
(Switzerland), (vi) Canadian Critical Care Trials Group, and
(vii) University of Kansas Cancer Center (KUCC) research
group. Further networks are being contacted. In addition,
we also plan to include RCTs via the clinicalstudydatare-
quest.com website.
Considering the abovementioned sources of RCTs, we
estimate that individual patient recruitment data of at
least 300 RCTs will be available for this project. This is a
convenience sample. We aim to include as many RCTs
from different fields of healthcare as possible.
Data collection and research ethics
We will collect the following data (among other):
1. Patient-level: Date of randomization.
2. Site-level: Date when a trial site was activated and
when it was closed (if available), country, total of
recruited/randomized patients, number of eligible
patients who declined to participate (if available),
and whether the site is at the institution of the
principal investigator (if available).
3. Trial-level (trial characteristics): Patient population,
medical field, type of intervention (e.g., drug
intervention), blinding status, target sample size
(includes statistical sample size and overall
recruitment goal [if available]), anticipated
recruitment time, number of trial sites, involved
countries, setting of recruitment (e.g., intensive
care), primary endpoint, trial completion status (if
discontinued, reason for the discontinuation), and
funding sources. Information on trial characteristics
is taken from the recruitment data source, trial
protocols (preferred option if available), journal
publications, or trial registries.
Definitions
The “recruitment target” is the planned number of
patients to be randomized as reported in the latest
version of the respective RCT protocol; the primary
journal publication, i.e., the one reporting the primary
outcome results; or the latest update of the trial registry
entry (in descending order in case of discrepancies). In
case no target sample size, but target number of events
is reported (e.g., in case of a time-to-event outcome), we
will take the approximate number of patients needed if
reported; otherwise, the RCT will be excluded from the
analyses outlined below. We will record the calculated
sample size as well as the recruitment target. This is to
account for the fact that trial teams often inflate the
calculated sample size to allow for some losses-to-
follow-up, which means the statistically required sample
size is typically smaller than the recruitment target.
“Recruitment time” is defined as the time (in days/
months) from the date of the first patient randomized to
the date of last patient randomized. Where available, we
will also consider the time from trial activation until the
date of last patient randomized to account for the
possible gap between trial activation and first patient
randomized.
“Anticipated recruitment time” is defined as the total re-
cruitment time the investigators anticipated for complet-
ing patient recruitment at the planning stage before the
RCT was initiated (i.e., before first patient randomized).
The “cumulative participant recruitment” is the
participant total recruited over the recruitment time
(absolute number) or the proportion of the target
sample size recruited over the recruitment time.
We define “interim landmarks” based on the recruit-
ment time and the proportion of target sample size (and
recruitment target) recruited during the RCT recruit-
ment time. For the interim landmarks based on time, we
will use months 1, 3, 6, 9, and 12 after RCT initiation.
For the landmarks based on the proportion of target
sample size, we will use 10% intervals (e.g., 10%, 20%, or
30% of target sample size recruited).
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We will consider an RCT to be prematurely discontinued
if the investigators who provide individual recruitment data
indicate recruitment discontinuation for one of the follow-
ing or any other reasons:
1. Poor recruitment (less than 90% of the statistical
sample size; 80% or less for sensitivity analysis)
2. Benefit
3. Futility (for reason other than poor recruitment)
4. External evidence
5. Harm
6. Other administrative reasons
If no direct contact to the investigators is possible, we
will rely on published reports (e.g., journal publications,
trial registries) to determine the reason for discontinu-
ation. In case the achieved sample size is below 90% of
the target sample size (or 80% for sensitivity analysis)
and no reason is identifiable, we will categorize the RCT
as discontinued and record “due to unknown reason.”
All other RCTs not meeting abovementioned criteria
will be considered completed.
Analysis
We will summarize and present the characteristics of all in-
cluded RCTs using descriptive statistics (means, medians,
ranges, and frequencies or proportions as appropriate).
For each RCT, we will calculate the total recruitment
time in months. Data on cumulative recruitment of
participants will be presented by plotting the number of
patients—expressed as proportion of the original recruit-
ment target to facilitate comparison across trials—over
time separately for each RCT; the resulting plots we will
call recruitment trajectories. We will also provide overall
averaged recruitment rates (total number of recruited
patients/recruitment time [months]) for each RCT.
For the following analyses, we will mainly consider
RCTs that have been completed or where recruitment
has been discontinued due to poor recruitment. RCTs
stopped for other reasons than poor recruitment will be
included for additional sensitivity analyses.
We aim to examine the following (inspired by findings
from Haidich and Ioannidis [14–16]): (1) associations
between study site recruitment and speed of participant
recruitment (e.g., recruitment trajectories for RCTs with
more than 80% of recruiting sites ready to recruit partic-
ipants within the first month versus those RCTs with
less than 80%), (2) investigation of seasonal differences
of participant recruitment rates [16], (3) associations
between early recruitment trajectory slopes and overall
recruitment success (i.e., achievement of more than 90%
of the target sample size), and (4) investigation of how
the recruitment time matches the anticipated recruit-
ment time at the planning stage. However, based on our
previous experience [5, 17], we assume that the antici-
pated time of patient recruitment will not be available
for most RCTs (be it on protocol or journal publication
level).
In further analyses, we will check whether the findings
from Haidich and Ioannidis (i.e., recruitment slope of
first 1–2months of a trial is highly predictive of further
patient recruitment) hold true for RCTs outside the
AIDS Clinical Trials Group. For this, we will split the
dataset into those RCTs used by Haidich and Ioannidis
and all others. Specifically, we will investigate the follow-
ing: (1) the extent to which speed of recruitment during
the first 3 months will correlate with the proportion of
RCTs for which the target sample size was attained; (2)
the extent to which recruitment during the first month
or two will correlate with subsequent recruitment; (3)
the extent to which the acceleration of recruitment in
the first 2 months (the ratio of second to first month
accrual) was also related significantly to the eventual
accrual; (4) whether the more patients were enrolled in
the first 2 months, the greater the absolute enrolment
and the proportion of target enrolment eventually
achieved; (5) whether all trials that recruit < 30% of their
target sample size after 10 months fail to reach their
target eventually; and (6) whether no trials show marked
acceleration of accrual over time.
Based on our systematic search and earlier reviews [7, 18],
the Bayesian model developed by Jiang et al. [12] is the
only model that comes with a freely available software
package (written for R [www.r-project.org]) dedicated
to predicting recruitment in clinical studies. We will there-
fore investigate the validity of this prediction model at base-
line (before start of recruitment) and at the mentioned
interim landmarks guided by the following questions:
– How large is the difference (in months) between the
model estimate and the actual recruitment time?
– In how many cases does the 95% credible interval
(of the predicted estimate) include the actual
recruitment time?
– How do the accuracy and precision of prediction
increase over time if model estimates are calculated
at interim landmarks (e.g., months 1, 3, 6, 9, 12) or
according to achieved recruitment (e.g., 10%, 20%,
or 50% of target sample size)?
– How do different assumptions (e.g., informative or
non-informative priors) influence prediction
accuracy?
– In case of multicenter trials, how does the
prediction change if the date of site activation is
considered in such a prediction model?
Simple linear regression models following a frequentist
approach are commonly used to predict the future
Kasenda et al. Trials          (2020) 21:731 Page 4 of 7
recruitment process, which assume that the accrual rate
is constant for each individual trial or individual trial
sites. To investigate whether the more flexible Bayesian
recruitment model, which takes into account informa-
tion on accrual accumulated up to a monitoring point in
the study in addition to including prior information
from historical data, provides better estimates for re-
cruitment prediction, we will compare the two models
with respect to the following:
1. The accuracy of accrual prediction (number of
participants, n) at expected trial duration time (T).
2. The accuracy of recruitment duration prediction
(how long will the trial take, T) to reach the target
sample size of n participants.
For the prediction of number of patients recruited at a
specific time point, we will assume the information of
early accrual to be known. Based on the information from
the early recruitment frame, we will first calculate the ac-
crual prediction using both methods (simple linear model
versus Bayesian model). To quantify the respective model
performance, we will calculate the percent error (%Rbias)
statistic: %Rbias = |Predicted −True|/True × 100%.
Here, “Predicted” means the predicted value by the
model and “True” means the actual number of patients
recruited. We will calculate %Rbias at different time
points. In addition, the %Rbias will be visually displayed
over time. For example, we will compare the %Rbias of
the two methods from 1 to 12 months of recruitment
time for each RCT.
In addition, to predict the number of participants
recruited, Bayesian methods can also provide a 95% pre-
diction interval for the anticipated trial completion time,
which can be used to determine whether a trial is slow
or on-target with respect to accrual. The RCTs can be
identified as having slow accrual if their anticipated
completion time, T, is smaller than the lower bound of
the prediction interval of completion time TPred. Fur-
thermore, the Bayesian model can identify studies with
high risk of accrual failure by estimating the probability
that a trial will achieve its accrual target late. The
probability of being late by a given time (Plate) offers an
effective way of monitoring recruitment progress and
facilitates decision-making for strategically allocating
resources. For example, to estimate the risk for a trial,
we can draw 50,000 Markov-Chain Monte-Carlo
(MCMC) samples from the Bayesian posterior predictive
distribution for TPred. The percentage of posterior
predictive draws of TPred that are greater than the antici-
pated completion date T is the trial’s estimated risk of
accrual failure: PLate = Pr (TPred > T| Data).
Overall, we will summarize and compare these two
prediction outcomes. We will use different visualization
methods to illustrate the differences between the
Bayesian and the linear frequentist prediction models,
and the comparison between Plate and the recruitment
time of trial actually running.
This final step will bring together all the results from
the analyses described under points 1–3 into a freely
accessible tool. This tool should be user-friendly, and
the parameters needed to provide estimates should be
readily available for trial teams. The tool should help
trialists to (1) estimate required time for completion of
enrolment when planning the trial and (2) monitor and
adjust planning while conducting the trial. For instance,
if an investigator wants to estimate how long it will take
to recruit 400 participants to a surgical RCT comparing
two techniques for wound closure, it would be import-
ant to know how many sites were included in similar
trials and which recruitment rate one can expect at each
site. Also, the time lag between site activation and first
patients enrolled would be important information. The
tool could first provide clinical researchers with
estimates based on recruitment data from similar
surgical RCTs, preferably conducted in the same country
(depending on our findings whether medical field and
country are important predictors of recruitment time).
With these estimates, one could then build a recruit-
ment projection by adding sites and also by adding
uncertainties to account for various issues related to the
community (e.g., different degrees of interest and equi-
poise in the research question) or the center (e.g., differ-
ent research personnel and capacity). Uncertainties
could be modeled (e.g., + 10% time lag between approval
and first patient enrolled). During the conduct of the
trial, one could then step by step replace the initial
estimates by real-world recruitment data from the trial
to improve estimates on the time needed to recruit the
required number of patients or to simulate how much
time one could save if more sites were added. We will
develop such a tool with input from recruitment experts
and future users (trialists and trial coordinators), employ
user testing [19, 20], and will also compare the tool’s
usability and performance to another recently described
web-based tool [21].
Discussion
This project will address questions that clinical researchers,
funding bodies, and research ethics committees are often
confronted with: What are the chances that a specific trial
achieves its recruitment target? How long will it take to
recruit the target statistical sample size? When should
researchers decide about changes in their recruitment
strategy or about early trial discontinuation? The proposed
project aims to provide reliable answers to these questions
and an easy-to-apply tool for recruitment planning and
monitoring in order to successfully complete RCTs and to
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allow for the most efficient allocation of scarce research
resources. The current waste of valuable resources in
clinical research is a huge international challenge [22, 23],
and the need to increase efficiency of patient recruitment is
a fundamental problem for trial investigators [5]. Trials that
last longer than anticipated typically incur excessive
management and trial unit resources and, importantly,
delay the answer to research questions.
The strengths of our project include the fact that we
use an empirical, international, comprehensive, and con-
certed approach to tackle the global practical challenge
of reliably predicting and monitoring patient recruitment
in RCTs. To the best of our knowledge, there is no other
project comparable in size and scope. We will include a
broad variety of recent RCTs increasing the external
validity of our findings. By making our results, methods,
and the resulting tool accessible through a dedicated
website, we aim to further encourage other investigators
sharing recruitment data to further optimize the model
and broaden external validity.
Our project has several potential limitations. First,
within our data collection, we do not capture the
comprehensive planning and administrative process to
set up an RCT on national or international level. These
processes and speed of administration vary among coun-
tries (e.g., the time between ethical approval and the
start of the trial). Therefore, this part of the planning
phase cannot be part of our investigations and we can-
not adjust for regional differences. Second, several RCTs
with time to event outcomes (e.g., progression-free
survival) are planned and powered based on the number
of events observed over time and not a specific number
of patients needed to be recruited [24]. Different models
have been proposed to predict the occurrence of events
of interest in a study population [18]. Based on our data,
we cannot investigate this approach, because such time
to event data are not available to us in this cohort of
RCTs. Third, we anticipate that we will have only limited
information on the time points when centers have been
initiated and approved to recruit patients. As outlined
previously, recruitment of centers for multicenter RCTs
is also an important part of planning the recruitment
process [7]. However, we anticipate that we can only in-
vestigate this issue of site recruitment in a sub-sample of
RCTs where date of center activation is available.
Fourth, we cannot systematically capture and consider
the choices, rationale, or expertise of the investigators,
staff, or the research network in conducting RCTs,
which likely also affects the speed and ultimate success
of the patient recruitment process. Finally, we do not
have information on center characteristics that may also
influence recruitment performance.
In summary, we will investigate the process of
patient recruitment to reduce the risk of RCTs being
discontinued for poor recruitment and produce a tool
to support recruitment planning. We hope to contrib-
ute to the evidence base that will inform the conduct
of clinical research, and enhance its efficiency by the
comprehensive, concerted, international effort motiv-
ating this project.
Trial status
Data collection of the study is still ongoing (started
December 2016), and we anticipate finishing the pro-
ject by end of 2021.
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